Skip to main content

Table 1 Sorafenib HCC Assessment Randomized Protocol (SHARP) [1] and Asia-Pacific [2] study

From: Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

 

SHARP [1]

 

Asia-Pacific [2]

 

Endpoint

Sorafenib vs placebo

 

Sorafenib vs placebo

 
 

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

OS

10.7 vs 7.9 months,

0.69 (0.55 to 0.87)

< 0.001

6.5 vs 4.2 months,

0.68 (0.50 to 0.93)

0.014

TTSP

1.08 (0.88 to 1.31)

0.768

0.90 (0.67 to 1.22)

0.50

TTP

5.5 vs 2.8 months,

0.58 (0.45 to 0.74)

< 0.001

2.8 vs 1.4 months,

0.57 (0.42 to 0.79)

< 0.001

RR

2% vs 1%

 

3.3% vs 1.3%

 
  1. OS = overall survival; RR = response rate; TTP = time to tumor progression; TTSP = time to symptomatic progression.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us